Berns on Nephrology

 
 
  • Hyperkalemia Drugs: Questions Remain   More "head-to-head" comparisons are needed to determine which of these agents is most effective and safest for the treatment of hyperkalemia, says Dr Jeffrey Berns.
  • Incremental Hemodialysis: Is It Safe?   Incremental dialysis may help preserve residual renal function and improve patient survival, but more research is needed to address safety concerns, says Dr Jeffrey Berns.
  • IV Iron in Nondialyzed CKD 'Risky'   Dr Jeffrey Berns urges caution when using intravenous iron to treat iron deficiency anemia in CKD patients who are not on dialysis.
  • When Initiating Dialysis, Can eGFR Stand Alone?   New Japanese guidelines raise questions about whether creatinine levels are sufficient to determine the need for dialysis in chronic kidney disease, says Dr Jeffrey Berns.
  • 'Incredible, Depressing' Shortage of Peritoneal Dialysate   Dr Jeffrey Berns calls on industry and even the federal government to address a crisis that is limiting dialysis patients' treatment choices.
  • Triferic: Any Better Than IV Iron for Dialysis Patients?   A new iron preparation added to dialysate may have some advantages over IV iron, but it may have some drawbacks as well.
  • Vascular Access: What Do Patients Want?   Clinicians may not be paying enough attention to patients' concerns and questions about vascular access decisions.
  • Should Nephrologists Be PCPs to Late-Stage CKD Patients?   Proposals to improve the care of patients with CKD include new payment and patient management models.
  • Strict BP Control in CKD: Hidden Benefits?   Tight blood pressure control may not slow progression of kidney disease, but might it delay mortality?
  • Skipping CKD 'Stage' With Your Patients   CKD stages introduce needless worry in some patients. It's time to shift the dialogue to the levels of kidney function and what they mean, says Dr Jeffrey Berns.
  • Nephrology in China: Similarities, Differences Astound   Dr Jeffrey Berns reflects on a recent trip to China where he learned first-hand about the challenges and opportunities faced by nephrologists and kidney patients there.
  • CPR for ESRD Patients? It's Time to Talk…   Too many patients with end-stage renal disease (ESRD) receive CPR while in the hospital, says Dr Jeffrey Berns, which suggests an opportunity for discussions about end-of-life care.
  • 'Morbid and Deadly' Drug Combinations to Avoid   Dr Jeffrey Berns reminds clinicians to be vigilant about the medications their patients take, both prescription and over-the-counter.
  • Measuring GFR in the ICU: Best Practices?   Better tools are desperately needed to measure kidney function in critical care patients, says Dr Jeffrey Berns.
  • Controversy Brews Over 'Dehydration' in Stroke   Dr Jeffrey Berns comments on research released at a recent stroke conference that he says may have made a basic blunder.
  • Patients May Not Understand Our Guidance   Clinicians need to consider patients' literacy levels to make sure that they understand any follow-up care, said Dr Jeffrey Berns.
  • 'Postmortem' of the SYMPLICITY HTN-3 Trial   Why were results of SYMPLICITY HTN-3 at odds with previous similar studies? Dr Berns interviews Dr Ray Townsend, a trial insider, to clarify the findings.
  • IV Iron: Are We Harming Dialysis Patients?   Dr Jeffrey S. Berns discusses a recent study that bolsters findings that call into question the practice of administering large amounts of IV iron to patients with end-stage renal disease.
  • New DOPPS Data Offer 'State of Dialysis' Message   Dr Jeffrey Berns provides take-away messages from the mound of new data released by the Dialysis Outcomes and Practice Patterns Study (DOPPS).
  • Nephrology Report Signals Trouble for Specialty   Dr Jeffrey Berns comments on the nephrology fellowship survey, which confirms declining interest in the specialty and trouble finding jobs for new nephrologists.